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ABSTRACT
Background: Not only monotherapy with inhaled corticosteroids (ICS) but also the concurrent use of other
antiasthmatic agents, including leukotriene receptor antagonists (LTRA), play an important role in the manage-
ment of asthma. However, few studies have focused on compliance with these drugs and on the relation be-
tween drug compliance and drug usage.
Methods: Data were derived from a survey of pharmacists dispensing antiasthmatic drugs to adults with
asthma who visited participating pharmacies from October through November 2002. The patients were limited
to regular users of ICS whose medication had not been changed for at least 6 months before the survey. Drug
compliance and the daily administration frequency of antiasthmatic agents were evaluated on the basis of phar-
maceutical records.
Results: Completed data were received for 322 patients. ICS compliance was lower than compliance with oral
sustained-released theophylline (OSRT) and compliance with LTRA. ICS compliance significantly correlated
with OSRT compliance and with LTRA compliance. There were no significant differences of ICS compliance
among ICS alone, ICS + LTRA, ICS + OSRT and ICS + LTRA + OSRT group, while the daily inhalation fre-
quency in ICS + OSRT or ICS + OSRT + LTRA group were higher than those in ICS alone group. Although
there was a significant negative correlation between ICS compliance and daily inhalation frequency, neither
OSRT compliance nor LTRA compliance significantly correlated with the tablet or capsule numbers per day.
These findings indicate that OSRT may increase the compliance of concomitant ICS, and that the compliance
of OSRT or LTRA is independent of the numbers of tablets taken per day.
Conclusions: These unique characteristics should be considered in the treatment and guidance of patients
with bronchial asthma.
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Table 1 Patient background
PA (%)duration (mean＋/−SD)age (mean＋/−SD)gender (male/female/UN)subgroup
16.9% (UN: 1.5%)15.7＋/−14.348.7＋/−17.9 23/41/1ICS alone
15.8% (UN: 0.0%)10.6＋/−9.853.0＋/−15.6  5/14/0ICS＋LTRA
20.3% (UN: 2.1%)14.5＋/−14.957.7＋/−18.4*** 71/66/6*, #ICS＋OSRT
29.5% (UN: 3.2%)14.5＋/−12.757.3＋/−17.2** 34/58/3¥ICS＋LTRA＋OSRT
22.0% (UN: 2.2%)14.5＋/−13.955.5＋/−18.1133/179/10al patients
**: P＜0.01, ***P＜0.001 vs. ICS alone, #: P＜0.05 vs. ICS＋LTRA, ¥: P＜0.05 vs. ICS＋OSRT, ICS alone: inhaled corticosteroid, 
LTRA: leukotrien receptor antagonist, OSRT: oral sustained-released theophyline, PA: presence of asthma atacks during the two weeks 
prior to answering the questionnaire, UN: unkown
Table 2-a The compliances with ICS, OSRT and LTRA
82.3＋/−23.6 (n＝322)ICS compliance
89.8＋/−18.2 (n＝238)**OSRT compliance
91.2＋/−17.4 (n＝114)**LTRA compliance
**: P＜ 0.01 vs. ICS compliance,  Wilcoxon’ ssigned-rank test 
with Bonferoni’ scorection
INTRODUCTION
Guidelines from various countries recommend in-
haled corticosteroids (ICS) for the primary treatment
of bronchial asthma in adults.1,2 Increased use of ICS
has led to dramatic improvement in the management
of asthma.3 Recently, inhaled long-acting beta 2 ago-
nists ( LABA ) , leukotriene receptor antagonists
( LTRA ) , or oral sustained-released theophylline
(OSRT) have been reported to be useful when added
to ICS in patients with persistent symptoms of asthma
that do not respond to ICS alone.4-6 Combinations of
ICS with other drugs are therefore playing an in-
creasingly important role in the management of
asthma.
Drug compliance is an important determinant of
the effectiveness of medical therapy in various types
of disease.7 In daily clinical practice , individual pa-
tients’ disease status and compliance with prescribed
medical therapy are most likely consciously or uncon-
sciously considered , regardless of the specific dis-
ease being treated. Drug compliance is also an impor-
tant factor in the design of strategies for the treat-
ment of asthma.
Drug compliance itself can be influenced by vari-
ous factors.8 The relation of compliance to daily dose
and administration frequency has been studied exten-
sively.9,10 The need for frequent daily administration
generally results in poorer drug compliance . How-
ever , studies of drug compliance in patients with
bronchial asthma are scare. In contrast to other com-
mon diseases, inhalation therapy has a major role in
the management of asthma. Therefore, drug compli-
ance should be assessed for both inhaled and oral
drugs. Although compliance with antiasthmatic medi-
cation has been studied previously and the negative
correlation was reported between the inhalation fre-
quency and the compliance in ICS,11,12 many points
remain unclear regarding the relation of the compli-
ance of used drugs, including ICS, LTRA and OSRT,
which are administrated to the same patient. More-
over, there are no established relations between the
administration frequency and the compliance with
OSRT and LTRA.
This study compared compliance among ICS ,
OSRT, and LTRA. We also analyzed the relations be-
tween compliance with each type of drug and the
daily administration frequency. To analyze factors af-
fecting compliance , we surveyed pharmacists who
dispensed antiasthmatic drugs to adults with asthma
who were regular users of ICS and resided in Niigata
Prefecture in 2002.
METHODS
The survey for this study was performed from Octo-
ber through November 2002 under the Ethical Princi-
ples for Medical Research Involving Human Subjects,
Declaration of Helsinki. The subjects were patients
who regularly used ICS dispensed by the pharmacies
participating in this survey . Patients 16 years or
younger were excluded. None of the subjects had
had any change in their prescription for at least 6
months prior to responding to the survey. Sixty dis-
pensing pharmacies in Niigata Prefecture, Japan par-
ticipated in the survey. Completed data were received
for 322 patients.
The patients’ pharmacists were questioned for the
daily administration frequency of drugs used to treat
asthma, including ICS, OSRT, and LTRA, prescribed
by each patient’s physician. The pharmacists also re-
ported data related to drug compliance, which was
calculated on the basis of the estimated total quantity
of medicines prescribed during the past 6 months
(QE) and the quantity of medicines actually taken
back home by the patient during the same period
(QA). Drug compliance was then expressed as a ra-
tio, calculated using the following formula: QAQE ×
100 (% from 0 to 100). Drug compliance was sepa-
rately calculated for ICS, OSRT, and LTRA. Any com-
pliance score greater than 100 was expressed as 100.
The statistical significance of the differences be-
548 Allergology International Vol 54, No4, 2005 www.jsaweb.jp
Hasegawa T et al.
ICS compliance (%)ICS P/DICS Ti/DICS P/Tisubgroup
83.9＋/−23.82.68＋/−1.501.86＋/−0.501.40＋/−0.58ICS alone
94.7＋/−10.22.74＋/−1.151.90＋/−0.321.42＋/−0.51ICS＋LTRA
81.4＋/−23.13.76＋/−2.52***2.21＋/−0.64***1.65＋/−0.79 *ICS＋OSRT
80.2＋/−25.43.30＋/−1.71***2.04＋/−0.44**1.59＋/−0.71ICS＋LTRA＋OSRT
82.3＋/−23.63.34＋/−2.072.07＋/−0.561.57＋/−0.72al patients
Each value was expressed as mean＋/−SD. *: P＜0.05, **: P＜0.01, ***: P＜0.001 vs. ICS alone, ICS alone: inhaled corticosteroid, 
LTRA: leukotrien receptor antagonist, OSRT: oral sustained-released theophyline, P/Ti: puf or blister numbers per one inhalation time, P/ 
D: puf or blister numbers a day, Ti/D: inhalation times a day
Table 2-b The background of ICS use and the compliance with ICS
Table 2-c The background of LTRA/OSRT use and the compliance with LTRA/OSRT
LTRA compliance (%)LTRA Ta/D
OSRT
Compliance (%)
OSRT Do/DOSRT Ta/Dsubgroup
ICS alone
85.9＋/−25.83.11＋/−1.24ICS＋LTRA
89.9＋/−17.9339＋/−1092.56＋/−1.24ICS＋OSRT
92.0＋/−15.43.52＋/−1.0389.2＋/−19.1346＋/−1092.63＋/−1.41ICS＋LTRA＋OSRT
91.0＋/−17.63.45＋/−1.0789.8＋/−18.3342＋/−1092.58＋/−1.30al patients
Each value was expressed as mean＋/−SD. Do/D: dose a day (mg/day), ICS alone: inhaled corticosteroid, LTRA: leukotrien receptor 
antagonist, OSRT: oral sustained-released theophyline, Ta/D: tablet or capsule numbers a day
tween drug compliance scores was calculated by the
Wilcoxon’s signed rank test with Bonferroni’s correc-
tion. The correlation of ICS compliance with OSRT or
LTRA compliance was evaluated by the Spearman’s
rank-correlation test. The correlations of compliance
with the daily inhalation frequency of ICS or the num-
bers of tabletscapsules of OSRT and LTRA adminis-
tered daily were also evaluated by the Spearman’s
rank-correlation test . The data were analyzed on a
Macintosh computer with StatView software, version
J-5.0. P values of less than 0.05 were considered to in-
dicate statistical significance.
RESULTS
The clinical characteristics of the subjects are sum-
marized in Table 1. In all patients , mean age was
55.5 ± 18.1 years, and the mean duration of disease
was 14.5 ± 13.9 years. As for gender, 42.6% of the sub-
jects were male, 57.4% were female, and 0.1% was un-
known. As for asthma control, 22.0% of the subjects
had had asthmatic attacks during the 2 weeks prior to
the study; asthma status was unknown for 2.2%. To
express further details, the cases were divided into
four subgroups (ICS alone group, ICS + LTRA group,
ICS + OSRT group, ICS + LTRA + OSRT group). The
gender ratio in the ICS + OSRT group showed a sig-
nificant difference compared with that in ICS alone
and the ICS + LTRA group, and the gender ratio in
the ICS + LTRA + OSRT group also showed a signifi-
cant difference compared with the ICS + OSRT
group. Both the age in the ICS + OSRT and the ICS +
LTRA + OSRT group indicated a significant difference
compared with that in ICS alone.
In all patients , mean compliance scores for ICS,
OSRT, and LTRA are shown in Table 2-a. The compli-
ance rate was higher than 80% for all three types of
drugs . However , the compliance with OSRT and
LTRA was significantly better than compliance with
ICS. And Table 2-b shows the puff or blister numbers
of ICS per one inhalation time (PTi), the inhalation
times of ICS a day (TiD), the puff or blister numbers
of ICS a day (PD) and the ICS compliance in each
subgroup as described above. Although PTi, TiD
and PD in the ICS + OSRT group were significantly
higher than those in the ICS alone group, there were
no significant differences of ICS compliance among
these groups. Table 2-c shows the tablet or capsule
numbers of OSRT or LTRA a day (TaD), the dose of
OSRT a day (DoD) and the OSRT or LTRA compli-
ance. There were no significant differences among
these subgroups.
The relations of ICS compliance to OSRT compli-
ance and LTRA compliance were examined. The re-
sults are shown in Figure 1. ICS compliance posi-
tively correlated with OSRT compliance as well as
with LTRA compliance (Fig. 1).
Next, the relation of drug compliance to PTi, TiD
and PD was examined. Figure 2 shows the results
for ICS. There was a significant negative correlation
of ICS compliance with the PTi (upper panel), TiD
(middle panel) and PD (lower panel) of ICS, al-
though the correlation coefficients were low. How-
ever, OSRT compliance did not correlate significantly
with the OSRT TaD (upper panel) and DoD (lower
panel) (Fig. 3). There was also no significant correla-
tion of LTRA compliance with the LTRA TaD
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Fig. 1 Corelation between ICS compliance and OSRT 
compliance (upper panel); and corelation between ICS 
compliance and LTRA compliance (lower panel). The data 
were evaluated by the Spearman’ srank-corelation test and 
were analyzed on a Macintosh computer with StatView soft-
ware, version J-5.0. Significant positive corelations were 
detected (P＜0.001).
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Fig. 2 Corelation between ICS compliance and the puf 
or blister numbers of ICS per one inhalation time (P/Ti: up-
per panel), the inhalation times of ICS administered per day 
(Ti/D: middle panel), the puf or blister numbers of ICS ad-
ministered per day (P/D: lower panel). The data were evalu-
ated by the Spearman’ srank-corelation test and were 
analyzed on a Macintosh computer with StatView software, 
version J-5.0. A significant negative corelation between 
ICS compliance and Ti/D, or ICS compliance and P/D was 
detected (P＜0.05).
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(Fig. 4).
DISCUSSION
Drug medications, including inhalation therapy, play
pivotal roles in the treatment of patients with bron-
chial asthma. Drug compliance with ICS, therefore,
has an important part in the management of asthma.
Moreover, other oral drugs for asthma control are
also considered important.4-6 Assessment of compli-
ance with ICS as well as compliance with concomitant
medication may help to delineate factors related to
drug response. The present study mainly compared
compliance among ICS, OSRT, and LTRA, and ana-
lyzed the relations between compliance with each
type of drug and the background of the drug use, in-
cluding PTi, Tid, TaD, using data obtained from
pharmacists who dispensed antiasthmatic drugs to
adults with asthma in Niigata Prefecture in 2002.
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Fig. 3 Corelation between OSRT compliance and the tab-
let or capsule numbers of OSRT administered per day 
(Ta/D: upper panel) and the dose of OSRT administered per 
day (Do/D: lower panel). The data were evaluated by the 
Spearman’ srank-corelation test and were analyzed on a 
Macintosh computer with StatView software, version J-5.0. 
A significant corelation was not detected (P＞0.05).
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Fig. 4 The corelation between LTRA compliance and 
the tablet or capsule numbers of LTRA administered per 
day. The data were evaluated by Spearman’ srank-corela-
tion test and were analyzed on a Macintosh computer with 
StatView software, version J-5.0. A significant corelation 
was not detected (P＞0.05).
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In several previous studies, ICS compliance was di-
rectly evaluated by counting the number of inhala-
tions by means of a mechanical counter attached to
inhalation devices,13-17 or compliance was calculated
on the basis of unused drugs returned by patients.18
However, such methods can introduce bias because
many patients are aware that their drug use is being
monitored during the study , which can influence
their compliance . However , the pharmaceutical-
record-based evaluation of drug compliance used in
this study can avoid such bias.
Comparison of compliance among antiasthmatic
drugs showed that compliance with OSRT was signifi-
cantly better than that with ICS, consistent with the
results of Kelloway et al.,19 in which almost the same
evaluating method for compliance had been per-
formed. As compared with their findings, however,
ICS compliance was better, and the difference in com-
pliance between OSRT and ICS was considerably
smaller. We attribute these differences to recently in-
creased awareness among both physicians and pa-
tients of the importance of asthma control by ICS.
LTRA also had better compliance than ICS, which ap-
parently conflicts with the results of our previous
study, showing no significant difference in compli-
ance between antiallergic drugs, including histamine
receptor 1 antagonists, and ICS.20 Antiallergic drugs
other than LTRA have no bronchodilatory activity ,
whereas LTRA have bronchodilatory activity compa-
rable to that of OSRT. These characteristics appar-
ently resulted in similar compliance for LTRA and
OSRT in the present study. We also found that ICS
compliance positively correlated with LTRA compli-
ance as well as with OSRT compliance. Given recent
reports of synergism between ICS compliance and
compliance with LABA, 21,22 which was not available
in Japan at the time of our study, it is likely that im-
proved compliance with concomitant drugs that have
bronchodilatory activity may also improve compli-
ance with ICS. Moreover, Table 2-b showed that al-
though the PTi, TiD and PD in the ICS + OSRT or
the ICS + OSRT + LTRA group were obviously higher
than those in the ICS alone group, there were no sig-
nificant differences of ICS compliance among these
groups. On the other hand, the PTi, TiD and PD
in the ICS + LTRA group appeared the same as those
in the ICS alone group, and the ICS compliance in the
ICS + LTRA group was better but not significant (P =
0.080) than that in the ICS alone group. These results
confirmed our speculation, because it was reported
that the more PTi, TiD and PD make the ICS
compliance worse,11,12 although the relation between
the compliance and the PTi, TiD and PD in this
Allergology International Vol 54, No4, 2005 www.jsaweb.jp 551
Analysis of Drug Compliance
study will be discussed later.
The daily administration frequency of drugs has
long been considered to affect drug compliance. Stud-
ies of hypertension treatment have shown that de-
creased daily administration frequency improves
antihypertensive-drug compliance.9,10 A study of an-
tiasthmatic drugs found no relation between drug
compliance and the daily administration frequency of
ICS or OSRT.19 However, a recent survey indicated
that increased daily administration frequency of ICS
is associated with decreased compliance with
ICS.11,12 Our analysis also clearly showed that in-
creased PTi, TiD and PD of ICS was clearly re-
lated to decreased compliance with ICS (Fig . 2).
These findings suggested that increased ICS compli-
ance due to heightened awareness of the importance
of ICS in asthma treatment most distinctly affected
patients with asthma who used ICS in a lower fre-
quency of administration. Our results for OSRT com-
pliance were consistent with Kelloway et al..19 As for
the relation between LTRA compliance and TaD of
LTRA, we found no previous studies in the literature
and believe that ours is the first to address this issue.
Although the drugs used differed among our sub-
jects, our results indicated no relation between the
number of tabletscapsules administered per day and
drug compliance with LTRA . Taken together , the
commonly accepted principle that the factors influ-
encing drug compliance are similar to those for anti-
hypertensive agents does not appear to apply, similar
to OSRT and probably LTRA.
In summary , we examined the relations among
compliance with drugs used for asthma management
and the administration frequency of antiasthmatic
agents, focusing on ICS. Data were derived from a
survey of asthmatic patients’ pharmacists . We con-
clude that interactions among compliance with OSRT,
LTRA, and ICS, and the relations of drug compliance
to the daily administration frequency of these drugs,
such as PTi, TiD and PD, should be considered in
the treatment and guidance of patients with bronchial
asthma.
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